Sentiment Stocks

Amanda, I’m so glad you got that moment. You, Braelyn and Ben made those seconds count. ❤️ I’m sure @POTUS @realDonaldTrump sees the opportunity: a real DCVax cancer moonshot, making the pursuit of cancer cures a defining part of his agenda. @DrOzCMS @SecKennedy @WhiteHouse @FDA, please grant DCVax-L a National Priority Voucher, extend the Plausible Mechanism Pathway to include it, and open compassionate access here in the United States. Let’s bring Braelyn’s treatment home. #DCVaxForBraelyn #DCVax 🙏🏻🙏🏻🙏🏻

$NWBO 𝗗𝗖𝗩𝗮𝘅-𝗟: 𝗡𝗛𝗦𝗕𝗧 𝗖𝗢𝗟𝗟𝗘𝗖𝗧𝗜𝗢𝗡𝗦 𝗔𝗥𝗘 𝗟𝗜𝗩𝗘. 𝗖𝗨𝗥𝗥𝗘𝗡𝗧 𝗔𝗖𝗖𝗘𝗦𝗦 𝗔𝗡𝗗 𝗖𝗢𝗠𝗠𝗘𝗥𝗖𝗜𝗔𝗟 𝗣𝗥𝗘𝗣𝗔𝗥𝗔𝗧𝗜𝗢𝗡 𝗔𝗥𝗘 𝗠𝗢𝗩𝗜𝗡𝗚 𝗧𝗢𝗚𝗘𝗧𝗛𝗘𝗥. I contacted NHSBT directly to clarify what is operational, how patients enter the pathway, and what the collaboration is intended to support. Their response confirms: “Yes, the service is currently live and collections have already begun.” 𝗟𝗲𝗲𝗱𝘀 𝗮𝗻𝗱 𝗢𝘅𝗳𝗼𝗿𝗱 𝗮𝗿𝗲 𝗼𝗽𝗲𝗻. DCVax-L patient collections through NHSBT are happening now. 𝗕𝗢𝗧𝗛 𝗕𝗘𝗙𝗢𝗥𝗘 𝗔𝗡𝗗 𝗔𝗙𝗧𝗘𝗥 𝗔𝗣𝗣𝗥𝗢𝗩𝗔𝗟 I specifically asked whether the collaboration supports existing compassionate-use/unlicensed treatment arrangements, preparation for commercial rollout following MHRA marketing authorisation, or both. The answer: “Both.” That establishes the purpose of this infrastructure: serving patients under current access arrangements while preparing to support commercial use following an approval. 𝗘𝗫𝗣𝗔𝗡𝗦𝗜𝗢𝗡 𝗜𝗦 𝗣𝗥𝗢𝗕𝗔𝗕𝗟𝗘 𝗕𝗘𝗙𝗢𝗥𝗘 𝗠𝗔𝗥𝗞𝗘𝗧𝗜𝗡𝗚 𝗔𝗨𝗧𝗛𝗢𝗥𝗜𝗦𝗔𝗧𝗜𝗢𝗡 NHSBT’s exact wording: “Expansion is probable in advance of marketing authorisation.” Additional sites and potential start dates are already being negotiated. NHSBT said these details can be shared once confirmed. This means network development can progress before a regulatory decision. Leeds and Oxford are the two locations confirmed operational today; further locations are being actively discussed. 𝗧𝗛𝗘 𝗦𝗖𝗔𝗟𝗜𝗡𝗚 𝗦𝗜𝗚𝗡𝗜𝗙𝗜𝗖𝗔𝗡𝗖𝗘 NWBO and Advent already have functioning collection services within established NHSBT clinical infrastructure. Additional locations would extend that pathway geographically, connecting more patients with an essential step in personalised vaccine production. Current patient access, operational experience and preparation for broader commercial use are developing together. The email establishes a live service and an active expansion process. DCVax-specific annual collection capacity and manufacturing throughput were not provided. 𝗔 𝗖𝗢𝗡𝗖𝗥𝗘𝗧𝗘 𝗧𝗜𝗠𝗘𝗙𝗥𝗔𝗠𝗘 𝗔𝗡𝗗 𝗥𝗘𝗙𝗘𝗥𝗥𝗔𝗟 𝗥𝗢𝗨𝗧𝗘 NHSBT says it can usually accommodate a patient within 𝟮 𝘄𝗲𝗲𝗸𝘀. The referral pathway is: 𝗥𝗲𝗳𝗲𝗿𝗿𝗶𝗻𝗴 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁 → 𝗔𝗱𝘃𝗲𝗻𝘁 𝗕𝗶𝗼𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 → 𝗡𝗛𝗦𝗕𝗧. The consultant contacts Advent, which then makes the NHSBT referral. Physicians have an identified route into the collection service. The two-week timeframe applies to NHSBT’s stage. Advent’s separate waiting time was not confirmed, so the complete schedule through assessment, manufacturing and treatment still needs clarification. 𝗛𝗢𝗪 𝗖𝗨𝗥𝗥𝗘𝗡𝗧 𝗔𝗖𝗖𝗘𝗦𝗦 𝗜𝗦 𝗙𝗨𝗡𝗗𝗘𝗗 NHSBT confirmed that patients currently self-fund treatment because it is not commissioned by NHS England. NHSBT is delivering services within that pathway. Its participation does not establish NHS-funded treatment. Patient charges and NHSBT’s financial terms were not disclosed. 𝗧𝗛𝗘 “𝗔𝗟𝗟 𝗦𝗢𝗟𝗜𝗗 𝗧𝗨𝗠𝗢𝗨𝗥𝗦” 𝗤𝗨𝗘𝗦𝗧𝗜𝗢𝗡 My question about this wording, current patient eligibility and its relationship to the MHRA application was referred to Simon Cliffe for clarification. Her reply did not establish the scope of current eligibility across tumour types or a future approved indication. 𝗜 𝗛𝗔𝗩𝗘 𝗔𝗟𝗥𝗘𝗔𝗗𝗬 𝗦𝗘𝗡𝗧 𝗔 𝗙𝗢𝗟𝗟𝗢𝗪-𝗨𝗣 I am a physician and independent patient advocate. I do not work for NWBO or Advent. I am receiving substantial enquiries from patients and families, including people in the United States interested in UK access. I have sent another email asking for: • The appropriate Advent contact and a coordinator for the complete pathway. • Whether US physicians can initiate referrals directly or patients first need a UK consultant. • When NHSBT’s two-week timeframe begins, plus separate assessment and manufacturing waiting times. • Whether eligibility, tumour-tissue suitability, costs and appointments can be confirmed before international travel, and how many UK visits are required. • A written referral checklist that can be shared with patients and their physicians. Jemima also offered a call, which I welcomed in my reply. My aim is to help patients and their doctors understand the complete process and coordinate access to this operating service. Source: written correspondence with Jemima Churchhouse, Service Development Manager, NHSBT Therapeutic Apheresis Services, 12 October 2026. #DCVax #GBM #CancerImmunotherapy #UKLifeSciences #DCVaxForBraelyn Out of respect for the person who took the time to respond, I’m keeping direct screenshots of the email off X. I’m sharing the substantive information provided and am awaiting a response to my follow-up questions. I’ll share further clarification when I receive it.

$NWBO #DCVax #DCVaxForBraelyn #GBM #SolidTumors #CancerVaccines 𝗠𝗛𝗥𝗔’𝗦 𝗢𝗖𝗧𝗢𝗕𝗘𝗥 𝟵 𝗨𝗣𝗗𝗔𝗧𝗘: 𝗗𝗖𝗩𝗮𝘅 𝗪𝗛𝗔𝗧 𝗖𝗛𝗔𝗡𝗚𝗘𝗗 On October 9, 2026, MHRA published its real-world evidence (RWE) hub and linked its July 2 data-requirements paper, which was not revised that day. The hub names no company or application, but it says many external-control principles would be relevant to completed-trial controls, the kind DCVax-L used. The 2021 real-world-data (RWD) guidance is established; the May 2025 external-control guideline remains a draft, with consultation ending in July. The hub joins methods for assessing existing comparisons with requirements for the next evidence. The July paper supports RWD for licensing where randomisation is impractical or unethical. It says linked data from the £600 million Health Data Research Service, announced in April 2025, could support earlier, more flexible approvals. 𝗖𝗟𝗜𝗡𝗜𝗖𝗔𝗟 𝗘𝗩𝗜𝗗𝗘𝗡𝗖𝗘 DCVax-L is under MHRA review, per Northwest. Its phase III randomised 331 patients 2:1 across four countries; 64 of 99 placebo patients crossed over after recurrence. The revised survival analysis used external trial controls: independent York Health Economics Consortium selected 1,366 newly diagnosed and 640 recurrent controls using 14 prespecified matching criteria, and substituting those controls into the 15 source trials reproduced whether each met its original endpoint. In newly diagnosed glioblastoma (GBM), median survival from randomisation was 19.3 versus 16.5 months, and five-year estimates were 13.0% versus 5.7%. From recurrence, median survival was 13.2 versus 7.8 months. The original randomised progression-free-survival comparison found no benefit: 6.2 versus 7.6 months, p=0.47. Readers disagreed on 256 of 494 possible-progression imaging time points, and investigators describe difficulty distinguishing progression from treatment-related changes. The survival case depends on a fair external comparison. MHRA’s draft prefers randomisation where feasible and accepts convincing alternatives. Barriers, delay and objective endpoints matter; late controls need justified selection, and multiple comparators test robustness. Effect size matters too: large, durable effects are more interpretable than differences readily explained by selection. Propensity-score matching (PSM) pairs patients with similar pretreatment probabilities of receiving treatment. INSIGhT tested it in newly diagnosed MGMT-unmethylated glioblastoma: external and randomised controls had comparable survival (HR 0.99; 95% CI 0.76–1.28). This tests the method, not DCVax’s effect, and needs adequate confounder data. In that setting, propensity-matched external controls recovered the randomised trial’s no-benefit result for three drugs. Without individual control records, the original publication used matching-adjusted indirect comparison rather than PSM. Northwest’s July 8, 2026, report from the British Neuro-Oncology Society conference used newly obtained records: PSM and inverse-probability weighting produced survival differences of 3.4–6.3 months versus the original 2.8, with sensitivity analyses for unmeasured confounding. These are company-reported conference analyses, not a peer-reviewed paper. The signal persisted. By June 2023, Northwest reported about 600 GBM patients treated, roughly 300 beyond phase III’s 296 in earlier trials or compassionate use, plus tens with other cancers. Its anecdotal compassionate observations cover patients into their late 80s, new batches after re-resection and continued use of an original batch after recurrence. At the December 29, 2025, annual meeting, management cited hundreds of compassionate-use patients and their growing RWD value, and planned access across most solid tumours, later with Direct. Those records can inform safety, durability, re-treatment and further uses. Evidence work starts with patients already treated. 𝗧𝗛𝗘 𝗡𝗛𝗦 𝗦𝗘𝗤𝗨𝗘𝗡𝗖𝗘 Two NHS developments came just before the hub. On October 6, 2026, Jessica Curtis’s 12:35 Cancer Vaccine Launch Pad (CVLP) talk preceded Marnix Bosch’s 12:55 keynote; CVLP refers NHS patients into supported vaccine and immunotherapy trials. On October 8, NHS Blood and Transplant (NHSBT) and Northwest announced a collaboration after months of joint work. NHSBT teams collect immune-cell starting material and support processing and handling, initially in Leeds and Oxford, with phased expansion explored. Northwest had reported leukapheresis delays and announced a dedicated clinic in April. NHSBT addresses that bottleneck; timely collection and treatment are measurable gains. 𝗧𝗛𝗘 𝗕𝗜𝗢𝗟𝗢𝗚𝗬 DCVax puts the patient’s cancer into the treatment’s design. DCVax-L loads prepared dendritic cells with broad patient-derived tumour antigens; presentation, costimulation and cell function shape the T-cell response. DCVax-Direct is designed to acquire tumour information within inoperable tumours, which can be unsuitable for surgery yet reachable by an image-guided needle. Each product and indication establishes its clinical case. Tumour information changes with the patient; manufacturing knowledge and delivery infrastructure can carry across uses. 𝗧𝗛𝗘 𝗗𝗔𝗧𝗔 𝗚𝗔𝗣 The July paper identifies missing hospital prescribing, including personalised medicines, in linked Clinical Practice Research Datalink health records: a death may be recorded while the treatment is missed. All-cause mortality is potentially measurable, directly relevant to DCVax-L’s survival outcome. Collection, release and administration records distinguish cells obtained, product available and treatment received. Link them, with process version and dosing, to baseline health, other treatments and follow-up, in complete, dated cohorts with comparators. Patient-reported outcomes, imaging, tumour response and service use complete the clinical and economic record; collect missing quality-of-life and cost measures prospectively. MHRA assesses fitness for the question: no universal regulatory-grade threshold exists, and imperfect records can support decisions. Establish what the evidence answers and collect what resolves uncertainty. Retain patients who deteriorate before treatment and align survival starting points to avoid selection and immortal-time bias. Measure waiting times, geography, collection and manufacture, and the proportion reaching treatment. Lawful basis, health-data protections and access controls govern linkage. The Data (Use and Access) Act 2025’s data-protection provisions, all in force by June 19, 2026, clarify commercial research and broad research consent. 𝗤𝗔𝗟𝗬𝘀 𝗔𝗡𝗗 𝗗𝗨𝗥𝗔𝗕𝗜𝗟𝗜𝗧𝗬 A quality-adjusted life year (QALY) combines survival and quality of life: one year in full health or two years at a health weight of 0.5 equals one QALY. NICE compares added QALYs with added NHS costs against usual care, including add-on treatment. Hypothetical, not DCVax data: 2 years × 0.6 = 1.2 QALYs; 4 × 0.8 = 3.2, a gain of 2. At £40,000 added NHS cost, one extra QALY costs £40,000; two cost £20,000 per QALY. SI 2026/202, effective March 24, 2026, enabled ministerial direction of NICE’s thresholds, and on April 2 NICE implemented £25,000–£35,000 per QALY for new and ongoing medicines evaluations. That range is a value benchmark, not a product price, and greater benefit carries the example below it. A median captures one point on a survival curve. Long-term survivors add QALYs beyond a modest median difference, so model DCVax-L’s five-year estimates alongside its 2.8-month median difference, with credible controls and complete follow-up. Severity weighting measures future health lost under current care against people of the same age and sex without the condition. Eligible populations receive QALY weights of 1.2 or 1.7: £40,000 for one added QALY becomes about £33,333 or £23,529 per weighted QALY. Establishing the applicable weight belongs in the GBM value case. The DCVax-L paper reports five possibly treatment-related serious adverse events across 2,151 doses. An appraisal models the full balance: longer survival can add care costs, while demonstrated tolerability and fewer admissions or later treatments can improve quality of life and reduce costs. NICE discounts costs and benefits at 3.5% yearly. It may consider 1.5% for both for sustained restoration of full or near-full health in people otherwise facing death or a very severely impaired life, with highly plausible long-term durability and irrecoverable costs addressed. Durable benefit changes how future gains count. 𝗡𝗛𝗦 𝗥𝗘𝗜𝗠𝗕𝗨𝗥𝗦𝗘𝗠𝗘𝗡𝗧 MHRA assesses quality, safety and benefit-risk; NICE assesses comparative benefit and value. DCVax-L’s ID836 appraisal for newly diagnosed glioblastoma is listed in progress, with publication to be confirmed. The company submits clinical and economic evidence to NICE and negotiates NHS England terms, often a confidential effective price. Licensing runs one clock; funded access runs a second. Northwest reported contracted reimbursement consultants and first-stage work by November 2024, and its annual report identifies upfront per-patient manufacturing costs and potentially different reimbursement arrangements. NICE can publish draft guidance before authorisation; aficamten’s cost-comparison appraisal produced final guidance alongside licensing, even outside formal aligned scheduling. ID836’s latest note records Northwest’s focus on the MHRA application and gives no completion date, and management’s stated launch plan did not wait for reimbursement. Evidence, terms and delivery can advance together during MHRA review. A routine-use recommendation normally creates a funding duty within 90 days. Cancer Drugs Fund (CDF) interim funding can begin after authorisation and a positive draft recommendation, whichever is later; transfer to routine budgets normally follows positive final guidance by 90 days, or 30 for specified Early Access to Medicines Scheme (EAMS) or cost-comparison cases. Missing training, facilities, materials or staff can justify longer funding implementation, so NHSBT’s operational role matters to how quickly a favourable decision reaches patients. 𝗙𝗨𝗡𝗗𝗘𝗗 𝗘𝗩𝗜𝗗𝗘𝗡𝗖𝗘 Managed access funds medicines with plausible cost-effectiveness potential and important uncertainties that further evidence can resolve, including outcomes collected during clinical practice. England’s CDF combines a data-collection agreement with commercial terms, collecting for the shortest sufficient period, up to five years, before reassessment. An unfavourable result ends new-patient managed access, while existing patients follow agreed continuation arrangements; successful reassessment supports routine funding. TA872 is an autologous cell-therapy precedent: axicabtagene ciloleucel moved into routine NHS use for a defined lymphoma population after assessment of trial follow-up, NHS Systemic Anti-Cancer Therapy (SACT) outcomes, costs and commercial terms. NHS outcomes were comparable with the trial. A treated/untreated registry supported Soliris expansion within paroxysmal nocturnal haemoglobinuria; Yescarta’s SCHOLAR-1 pooled two trials and two observational studies; Kymriah used three external datasets. A DCVax trial, registry or managed-access programme can connect access, production and evaluation, building the evidence for the later funding decision. 𝗛𝗢𝗦𝗣𝗜𝗧𝗔𝗟 𝗣𝗔𝗬𝗠𝗘𝗡𝗧 Hospital payment requires an eligible medicine and indication, Blueteq patient approval, and complete monthly costs through the Drugs Patient Level Contract Monitoring dataset (DrPLCM). Missing or late required SACT records can block cancer-drug payment, while prior-approval forms enter the medical record and may inform later NICE evaluations: documentation supports both payment and future appraisal. NHS systems link Blueteq and SACT by NHS number and check vital status. SACT’s wider collection includes EAMS, but the CDF evaluation cohort excludes treatment begun before CDF entry. SACT can answer agreed uncertainties when no trial continues. Providers claim eligible costs at the NICE-approved price on NHS England’s portal; NHS England validates and reimburses, and supply contracts pay manufacturers. DCVax’s contract must define the unit: batch, course, doses or another basis. Drug reimbursement excludes delivery, preparation on-costs, homecare handling and associated services, so assign funding for collection, processing, transport, administration and follow-up, accounting for what the product contract covers. A funded cell therapy needs a funded delivery pathway, and NHSBT and Advent make its capacity, responsibilities and costs assessable. NICE counts relevant additional costs, with justified supplementary apportionment for established service-change plans, formal agreements or multi-use technologies. Demonstrated shared use and cost allocation matter to a platform’s economic case. 𝗥𝗔𝗥𝗘 𝗖𝗔𝗡𝗖𝗘𝗥𝗦 Without an established anticancer therapy, the comparator is best supportive care, existing management or relevant treatments. That care has measurable survival, quality of life and costs, and natural-history data and prospective follow-up can establish the comparison. NICE’s Highly Specialised Technologies route starts at £100,000 per QALY but has narrow criteria: prevalence at most 1 in 50,000 in England, at most 300 eligible people, and additional disease and technology requirements. Repurposing and indication extensions face restrictions, so later platform uses cannot simply inherit this threshold. DCVax-L already has a standard appraisal route, where added health and the applicable severity weighting build its case. 𝗘𝗔𝗥𝗟𝗬 𝗔𝗖𝗖𝗘𝗦𝗦 DCVax-L received the first UK Promising Innovative Medicine (PIM) designation in September 2014, for all malignant gliomas, newly diagnosed and recurrent, including lower grades. PIMs reflect promise at designation but do not expire under current guidance, and a broad PIM within a defined condition can support successive scientific opinions for treatment lines or combinations without another PIM. Any new opinion follows current EAMS rules; DCVax-L’s malignant-glioma scope provides the starting point. EAMS became statutory on April 15, 2022. SI 2022/352 regulations 167C and 167H permit quality, safety and efficacy data collection without separate trial authorisation where MHRA agrees and consent is documented. Refusing data consent must not cost treatment, and data protections and other approvals remain. EAMS generally expects six months’ supply before authorisation or indication extension; NHS services still need funding, but the company supplies free medicine, including agreed winding-down. Other compassionate supply has distinct legal and payment routes, including Specials and hospital exemption. England’s Individual Funding Requests (IFRs) require clinical exceptionality, evidence of effectiveness and good resource use, and its commissioning list names murcidencel as not routinely commissioned, with access as per IFR approval: a named route for qualifying patients. 𝗢𝗙𝗙-𝗟𝗔𝗕𝗘𝗟 𝗨𝗦𝗘 𝗔𝗡𝗗 𝗡𝗘𝗪 𝗜𝗡𝗗𝗜𝗖𝗔𝗧𝗜𝗢𝗡𝗦 A first licence would open off-label prescribing beyond the approved indication where clinically justified. Prescribers need evidence or experience, informed consent, records, monitoring and adverse-reaction reporting. MHRA’s Specials hierarchy favours a suitable licensed product, even off-label, over an unlicensed alternative; cost or convenience alone cannot justify a Special. Off-label prescribing concerns use of the licensed product: it does not waive manufacturing or quality requirements, Direct is separate, and it does not create routine NHS funding. Reliable outcomes can support the next indication. Under current trial-specific risk rules, MHRA recognises robust RWD randomised trials for label changes, where a known safety profile can keep safety-data collection minimal. A new indication uses a Type II variation under a 120-day assessment procedure, with calendar timing affected by validation and responses. With the holder’s agreement, a standard authorisation can become conditional where benefit-risk is positive, need is unmet, comprehensive data are expected later, and immediate-access benefit outweighs evidential risk; obligations and annual reassessment then focus on the new indication. Unmet need includes major advantage over an existing therapy, so better outcomes matter to conditional authorisation as well as reimbursement. For a qualifying use, the sequence runs: optional EAMS access and data → an indication variation with conditional obligations → NICE appraisal and possible managed access. EAMS ends or winds down on the licensing decision. Guidance added the new-indication section in January 2026 and clarified procedures later that year. The May 2026 Investigational Marketing Authorisation proposal still requires legislation; conditional authorisation already exists. 𝗦𝗔𝗨𝗗𝗜 𝗔𝗥𝗔𝗕𝗜𝗔 The Saudi Food and Drug Authority (SFDA) issued its final RWD/RWE framework on April 20, 2026, and implemented it on July 20. It recognises propensity scores, external comparators and transportability: local covariate data can support transferring effects from multi-regional trials to Saudi patients. SFDA’s New Accelerator Program for Drugs in Rare Diseases (NADR), implemented September 5, 2026, covers pharmaceuticals and biologics for rare, life-threatening or seriously debilitating conditions affecting fewer than 5 in 10,000 Saudi residents, with unmet need or significant clinical benefit. Products can qualify during development, and UK approval is not required to seek designation. SFDA states it will assess a complete designation submission within 20 working days. Designation comes first; the framework calls for the marketing application within six months. NADR recognises prior platform knowledge, natural-history comparators where concurrent controls are infeasible, and priority, rolling and conditional review options, and its form expressly asks for compassionate/specials-use history. For unregistered UK sites, inspection will not bar registration when specified GMP documents, reports and fees are supplied. Ordinary FDA/EMA reliance routes exclude advanced therapies; NADR has its own eligibility and quality requirements. The clinical records and UK manufacturing dossier have a defined Saudi role. EU orphan designation dates to 2007, with sponsorship transferred to Northwest’s German subsidiary in 2012, and EMA’s historical EU glioma estimate was about 1 in 10,000. SFDA judges Saudi prevalence and unmet need; that designation history, with the 2014 UK PIM, belongs in the dossier. Northwest’s non-binding August 6, 2026, SPIMACO MOU contemplates DCVax-L’s Saudi application, commercialisation, supply, revenue sharing and separate technology-transfer/local-manufacturing agreements. Northwest retains IP; additional indications and Gulf Cooperation Council territories are contemplated. Definitive agreements and Saudi approval and payment decisions are required. A prospective partner connects the evidence strategy to commercial expansion. 𝗠𝗔𝗡𝗨𝗙𝗔𝗖𝗧𝗨𝗥𝗜𝗡𝗚 𝗔𝗡𝗗 𝗧𝗥𝗜𝗔𝗟𝗦 Advent brings manufacturing inside Northwest. Management said Sawston’s two Grade B suites could support initial launch before Grade C expansion. Changes and in-licensed technologies need traceability and comparability; Eden aims to expand capacity and reduce manual work. Since July 23, 2025, SI 2025/87 provides for eligible point-of-care and modular manufacture with a licensed control site and product-specific master files. Point-of-care requires a need to manufacture near use; modular deployment requires relocatable units and an MHRA determination. NHSBT collection and Eden automation alone do not establish eligibility. Wider deployment can retain central quality accountability. Clinical-trial reforms from April 28, 2026, provide combined MHRA and ethics review, normally with an initial decision within 30 days of validation; requests for information or conditions can follow. Advanced therapies retain full review and are excluded from automatic authorisation. Prior UK dossiers for the same product can be cross-referenced, retaining trial-specific manufacturing and labelling documents, so knowledge carries forward within each distinct L or Direct programme. UK law requires ICH GCP principles with regard to relevant annexes, including trial-system and laboratory oversight. E8 covers quality by design; E6(R3) Annex 2 covers pragmatic, decentralised and routine-data elements (EMA from January 15, 2027); M14 covers non-interventional safety studies; E23 effectiveness work continues. Integrated MHRA–NICE Scientific Advice joins regulatory and economic planning. The separate RWE Scientific Dialogue excludes products already in UK regulatory or health technology assessment. 𝗙𝗢𝗨𝗥 𝗡𝗛𝗦 𝗦𝗬𝗦𝗧𝗘𝗠𝗦 Since January 1, 2025, MHRA licensing is UK-wide under Windsor arrangements, but NHS funding remains nation-specific. Wales normally implements positive NICE recommendations within 60 days of final draft guidance. Its individual funding policy excludes retrospective funding and applies a different-circumstances test to rejected or out-of-policy uses; unappraised interventions need likely significant clinical benefit and reasonable value. Scotland uses Scottish Medicines Consortium appraisal, with patient and clinician engagement for rare or end-of-life conditions and interim acceptance routes; Northern Ireland endorses NICE appraisals. 𝗥𝗘𝗦𝗘𝗔𝗥𝗖𝗛 𝗔𝗡𝗗 𝗗𝗔𝗧𝗔 𝗜𝗡𝗙𝗥𝗔𝗦𝗧𝗥𝗨𝗖𝗧𝗨𝗥𝗘 Public research funding has its own role: NHS England funds CVLP infrastructure, NIHR funded ImmunoTACE’s dendritic-cell study, and NIHR’s Efficacy and Mechanism Evaluation (EME) programme accepts eligible proposals. Cell and Gene Therapy Catapult leads the advanced-therapy Centre of Excellence in Regulatory Science and Innovation. The September 2026 next-generation competition prioritises personalised care and novel platforms; any Northwest award or partnership would require its own agreement. A UK Study-A-Thon demonstrated distributed analysis, shared formats and the importance of coverage and local knowledge. MHRA’s data strategy and European and pharmacovigilance research reinforce the same requirements: governance, access, expertise and resources. 𝗧𝗛𝗘 𝗣𝗟𝗔𝗧𝗙𝗢𝗥𝗠 𝗜𝗠𝗣𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 Per-patient value and total budget are distinct, so align the evidence plan and the funding proposal: product, use, price, eligibility, delivery and service costs. Analyse independently and report transparently. DCVax supplies the patient-specific antigen strategy; Advent supplies manufacture; NHSBT supplies collection and handling. The paradigm shift: personalised treatment generates evidence, demonstrated benefit strengthens funding, and accumulated knowledge supports the next application for wider access.

The $NWBO #DCVax platform is antigen agnostic. It works on every disease. Steinman spent a career proving that the elegant addressed vaccine was the answer. His own cancer proved he'd asked the wrong question. The cell that won't respond to the perfect address isn't broken, it's converted. Irreversibly. So the solution isn't to address it better. It's to replace it. He discovered this by using manufactured cells on himself and getting four and a half years instead of six months. Then he refused to publish it as evidence, because one patient isn't a trial. He had spent decades arguing that mail delivery was the problem to solve. His own body proved the problem was that the recipient had moved and had no intention of moving back. One platform. Any payload. Built outside the field, delivered inside the body, instructing once. #DCVaxForBraelyn nitter.gq/andrewcaravello/status…